Cervical Cancer Awareness Month
Throughout January, IGCS will mark Cervical Cancer Awareness Month (CCAM) by highlighting the global burden of cervical cancer and what IGCS is doing to help eliminate this burden. We have also developed a social media toolkit so you too can play a part in driving awareness about cervical cancer this month.
IGCS supports the WHO Cervical Cancer Elimination Initiative to reduce the incidence of and mortality from cervical cancer by:
- Providing mentorship and training to healthcare professionals who care for women with preinvasive disease and cervical cancer.
- Patient advocacy programming and networking
Innovative Technologies for Cervical Cancer Prevention and Treatment
Kathleen Schmeler, MD
Dr. Schmeler discusses best practices for cervical cancer screening and treatment, including options for and solutions in middle- and low-resource settings.
ConCerv: A prospective trial of conservative surgery for low-risk, early-stage cervical cancer
Kathleen Schmeler, MD
Dr. Schmeler presents the findings of the ConCerv Clinical Trial, a study conducted from 2010-2019 to prospectively evaluate the feasibility of conservative surgery in women with early-stage, low-risk cervical cancer.
Advances in Cervical Cancer Therapeutics
2021 was an impactful year for cervix cancer therapeutics. IGCS President, Robert Coleman provided this overview for OncLive near the end of 2021 and here are the highlights:
The phase III EMPOWER trial demonstrated the clinically meaningful superiority of single-agent immunotherapy (cemiplimab) over standard single agent, physician’s choice chemotherapy in previously-treated metastatic/recurrent cervical cancer. The results were robust demonstrating superiority in PFS, OS and objective response and in multiple histologies. A regulatory decision this is expected this month. Learn more.
At the European Society for Medical Oncology (ESMO) Congress 2021, the positive results of KEYNOTE-826: pembrolizumab plus chemotherapy ± bevacizumab versus placebo plus chemotherapy ± bevacizumab for previously untreated persistent, recurrent, or metastatic cervical cancer were announced. The study showed that the addition of immunotherapy to our best frontline standard of platinum/paclitaxel/bevacizumab provided a clinically meaningful improvement in PFS and OS in all-comers as well as in PD-L1 positive tumors. FDA approved the 4 drug regimen in record time in October for treatment-naïve PD-L1 expressing tumors. Learn more.
Also, recently, tisotumab vedotin, an antibody drug conjugate targeting tissue factor was approved as second-line therapy for metastatic cervical cancer based on impressive objective and durable responses in patients whose tumors progressed after frontline chemotherapy. Finally, there were some hints of the expanded efficacy of tisotumab vedotin in combination with chemotherapy and in combination with immunotherapy as well as increased efficacy of dual immune checkpoint inhibitor therapy. Collectively, these findings provide real promise for future advances. Learn more.